In 2008, Mindray in its initial press release after the purchase of Datascope said that in 18 months it would realize a $30,000,000 "synergy" from merging China based R&D and manufacturing with U.S. based sales, service and marketing. It may be that Mindray after gradually moving more work over to China is finally in the position it hoped to be in at the start of 2010.
The company is essentially a low cost manufacturer of three classes of medical instruments - patient monitors, medical imaging systems and in-vitro diagnostic products. The company currently dominates the distribution channel in China, and is continuing to strengthen its distributor channels oversea. Its equipment are in general very attractively priced, yet have comparable or sometimes superior performance relative to existing equipment.
Lately, the company has been making deliberate acquisitions into the diagnostics and medical device space. IF the company is successful in adding these higher margin products into its sales mix, it may super-charge the company's revenue and income growth in the upcoming years. But that is a big IF, and we should wait and see.